First in human lung transplantation: adenosine a2a receptor agonist (regadenoson)
Background: Currently, no clinically available treatment exists for ischemia-reperfusion injury (IRI) following lung transplantation. Pre-clinical animal models have shown adenosine 2A receptor (A2AR) agonists are effective treatment options for reducing IRI. The purpose of this first in human study was to conduct a Phase I clinical trial to evaluate the safety of continuous infusion of an A2AR agonist in lung transplant recipients.Methods: An adaptive, 2-stage continual reassessment trial was designed to evaluate the safety of regadenoson (A2AR agonist) in the setting of lung transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Christine L. Lau, Jared P. Beller, Joshua A. Boys, Yunge Zhao, Jennifer Phillips, Michael Cosner, Mark R. Conaway, Gina Petroni, Eric J. Charles, J. Hunter Mehaffey, Hannah C. Mannem, Irving L. Kron, Alexander S. Krupnick, Joel Linden Tags: Original Clinical Science Source Type: research
More News: Boys | Cardiology | Clinical Trials | Heart | Heart Transplant | Lexiscan | Lung Transplant | Science | Study | Transplant Surgery | Transplants